Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-26.72 Insider Own1.50% Shs Outstand3.77M Perf Week-24.29%
Market Cap1.20M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.72M Perf Month-26.08%
Income-12.77M PEG- EPS next Q- Inst Own6.21% Short Float0.65% Perf Quarter-63.86%
Sales0.00M P/S- EPS this Y- Inst Trans6.59% Short Ratio0.09 Perf Half Y-94.40%
Book/sh0.88 P/B0.36 EPS next Y- ROA-382.23% Short Interest0.02M Perf Year-99.28%
Cash/sh1.08 P/C0.29 EPS next 5Y- ROE-903.08% 52W Range0.38 - 48.93 Perf YTD-88.20%
Dividend Est.- P/FCF- EPS past 5Y26.64% ROI-439.42% 52W High-99.35% Beta-1.49
Dividend TTM- Quick Ratio2.64 Sales past 5Y-20.00% Gross Margin- 52W Low-15.20% ATR (14)0.05
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM78.24% Oper. Margin0.00% RSI (14)27.38 Volatility19.16% 10.55%
Employees4 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2520.00
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q98.77% Payout- Rel Volume4.41 Prev Close0.41
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsApr 01 BMO Avg Volume262.06K Price0.32
SMA20-23.70% SMA50-40.54% SMA200-93.54% Trades Volume1,154,853 Change-23.00%
May-23-24 10:30AM
May-22-24 09:15AM
May-21-24 08:35AM
May-20-24 08:45AM
May-14-24 09:05AM
10:54AM Loading…
May-13-24 10:54AM
Apr-29-24 08:45AM
Apr-25-24 09:15AM
Apr-16-24 08:35AM
Apr-08-24 08:35AM
Apr-01-24 07:35AM
Mar-28-24 09:00AM
Mar-14-24 08:45AM
Mar-04-24 08:30AM
08:55AM Loading…
Feb-02-24 08:55AM
Jan-26-24 08:05AM
Dec-06-23 01:47PM
Dec-05-23 09:05AM
Nov-27-23 08:35AM
Nov-15-23 08:05AM
Oct-31-23 08:45AM
Oct-19-23 08:45AM
Oct-18-23 10:00AM
Oct-17-23 08:35AM
Oct-11-23 09:05AM
Oct-05-23 08:45AM
Sep-29-23 09:00AM
Sep-06-23 09:05AM
09:15AM Loading…
Sep-01-23 09:15AM
Aug-29-23 11:06AM
Aug-25-23 09:00AM
Aug-23-23 09:00AM
Aug-16-23 12:00PM
Aug-14-23 08:05AM
Aug-07-23 08:35AM
Aug-03-23 08:30AM
Jul-26-23 11:15AM
Jul-24-23 09:00AM
Jul-05-23 08:45AM
Jun-27-23 08:45AM
Jun-15-23 08:45AM
Jun-13-23 08:35AM
May-22-23 08:45AM
Apr-27-23 09:05AM
Apr-25-23 08:45AM
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.